Mizuho analyst Uy Ear lowered the firm’s price target on Neurocrine to $114 from $116 and keeps a Neutral rating on the shares. The company reported disappointing results from the last two expected trial readouts for 2023: NBI-1065846 in anhedonia related to major depressive disorder. and NBI-921352 in focal onset seizures, the analyst tells investors in a research note. Heading into the readouts, the firm had low confidence in seeing a clear signal for these Phase 2 trials.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NBIX:
- Neurocrine price target lowered to $125 from $135 at Barclays
- Xenon reports Neurocrine will not continue development of NBI-921352
- Neurocrine reports positive results of Ingrezza in chorea study
- Neurocrine price target raised to $170 from $165 at Oppenheimer
- Neurocrine price target raised to $116 from $113 at Mizuho